Business
AXIM Targets Cannabinoid-based Ophthalmic Solutions -- SECFilings.com
AXIM Targets Cannabinoid-based Ophthalmic Solutions -- SECFilings.com.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\n \n \n AXIM Targets Cannabinoid-based Ophthalmic Solutions -- SECFilings.com\n \n \nAXIM Targets Cannabinoid-based Ophthalmic Solutions -- SECFilings.com\n \n REDONDO BEACH, CA--(Marketwired - Oct 25, 2017) - SECFilings.com, a leading financial news and information portal offering free real-time public company filing alerts, announces the publication of an article covering the ophthalmology market and AXIM Biotechnologies Inc.'s (OTCQB: AXIM) cannabinoid-based therapies.\n Global ophthalmology revenue is forecast to grow at a 9.48% compound annual growth rate from $13.7 billion in 2015 to $26 billion by 2022, according to Research and Markets. Despite medical advances, most ophthalmic disorders cannot be cured and treatment is aimed at managing the disease indication to reduce the severity of symptoms and slow the progression of visual field loss over time.\n AXIM Biotechnologies believes that cannabinoids could play a big role in managing ophthalmology symptoms and potentially even reversing some diseases. With two programs in its clinical pipeline, the company is targeting glaucoma and dry eye -- two of the most prevalent ophthalmological conditions.\n Cannabinoid Potential in Ophthalmology\n The idea that cannabinoids can be helpful in treating glaucoma dates back to the 1970s. Studies conducted then showed that smoking marijuana lowered intraocular pressure (IOP) in people with glaucoma, but the effects only lasted for about three or four hours. In addition, smoking marijuana led to a decrease in blood pressure that may lead to a harmful reduction in blood flow to the already-vulnerable optic nerve.\n In 2000, researchers developed a non-psychotropic synthetic cannabinoid, HU-211, and found that a single dose reduced IOP by 5.3 mmHg (24% of baseline) in rabbits over a six hour period. Since the cannabinoid was administered locally, there was no systemic decrease in blood pressure that would have put the optic nerve at risk. These results showed that synthetic or non-whole-plant cannabinoids could play an important role in ophthalmology.\n Researchers have taken these findings and other breakthroughs and used them to expand into other areas of ophthalmology, ranging from dry eye to inflammatory diseases of the eye. Google Scholar lists about 600 papers published this year alone containing the words \"cannabinoid\" and \"oph...